Search Antibody Database

Found 9 matching records:

Displaying record number 1171

Download this epitope record as JSON.

MAb ID	TE135
HXB2 Location	Tat(1-20) DNA(5831..5890)	Tat Epitope Map
Author Location	Tat(1-20 Lai/Bru)
Research Contact	Dr. J.-L. Guesdon, Institut Pasteur, Paris
Epitope	`MEPVDPRLEPGSQPKT`	Epitope Alignment
Subtype	B
Ab Type	N-term
Neutralizing
Species (Isotype)	mouse(IgG)
Patient
Immunogen	vaccine
Keywords	subtype comparisons

Vaccine Details

Vaccine type	protein
Vaccine strain	B clade BRU
Vaccine component	Tat
Adjuvant	Complete Freund's Adjuvant (CFA)

Notes

Showing 1 of 1 note.

This is one of 5 anti-Tat murine monoclonal antibodies generated in this study. TE135 is clade B specific, and does not recognize Tat from clade A, C, D, or CRF01 (AE). It reacts strongly with aa 1-61, and is able to react with aa 1-20. Belliard2003 (subtype comparisons)

References

Showing 1 of 1 reference.

Belliard2003 Guillaume Belliard, Anthony Romieu, Jean François Zagury, Hayet Dali, Olivier Chaloin, Roger Le Grand, Erwann Loret, Jean Paul Briand, Bernard Roques, Claude Desgranges, and Sylviane Muller. Specificity and Effect on Apoptosis of Tat Antibodies from Vaccinated and SHIV-Infected Rhesus Macaques and HIV-Infected Individuals. Vaccine, 21(23):3186-3199, 4 Jul 2003. PubMed ID: 12804847. Show all entries for this paper.

Displaying record number 1168

Download this epitope record as JSON.

MAb ID	TD84
HXB2 Location	Tat(1-20) DNA(5831..5890)	Tat Epitope Map
Author Location	Tat(1-20 Lai/Bru)
Research Contact	Dr. J.-L. Guesdon, Institut Pasteur, Paris
Epitope	`MEPVDPRLEPGSQPKT`	Epitope Alignment
Subtype	B
Ab Type	N-term
Neutralizing
Species (Isotype)	mouse(IgG)
Patient
Immunogen	vaccine
Keywords	subtype comparisons

Vaccine Details

Vaccine type	protein
Vaccine strain	B clade BRU
Vaccine component	Tat
Adjuvant	Complete Freund's Adjuvant (CFA)

Notes

Showing 1 of 1 note.

This is one of 5 anti-Tat murine monoclonal antibodies generated in this study. TD84 is clade B specific, and does not recognize Tat from clade A, C, D, or CRF01 (AE). It reacts strongly with aa 1-61, and is able to react with aa 1-20. Belliard2003 (subtype comparisons)

References

Showing 1 of 1 reference.

Displaying record number 1169

Download this epitope record as JSON.

MAb ID	TA9
HXB2 Location	Tat(1-20) DNA(5831..5890)	Tat Epitope Map
Author Location	Tat(1-20 Lai/Bru)
Research Contact	Dr. J.-L. Guesdon, Institut Pasteur, Paris
Epitope	`MEPVDPRLEPGSQPKT`	Epitope Alignment
Subtype	B
Ab Type	N-term
Neutralizing
Species (Isotype)	mouse(IgG)
Patient
Immunogen	vaccine
Keywords	subtype comparisons

Vaccine Details

Vaccine type	protein
Vaccine strain	B clade BRU
Vaccine component	Tat
Adjuvant	Complete Freund's Adjuvant (CFA)

Notes

Showing 2 of 2 notes.

TA9: Similarity level of the TA9 binding site pentapeptide MEPVD to the host proteome was low, with the low-similarity 5-mer occurring in the host proteome 1 time, indicating that this peptide can be used to elicit Abs for active/passive immunotherapy with low risk of cross-reaction with the host proteome. Kanduc2008
This is one of 5 anti-Tat murine monoclonal antibodies generated in this study. TA9 is clade B specific, and does not recognize Tat from clade A, C, D, or CRF01 (AE).TA9 binds to the Tat peptide aa 1-61 strongly, and is also able to bind to Tat aa 1-20, and Tat peptide aa 8-53. Belliard2003 (subtype comparisons)

References

Showing 2 of 2 references.

Kanduc2008 Darja Kanduc, Rosario Serpico, Alberta Lucchese, and Yehuda Shoenfeld. Correlating Low-Similarity Peptide Sequences and HIV B-Cell Epitopes. Autoimmun. Rev., 7(4):291-296, Feb 2008. PubMed ID: 18295732. Show all entries for this paper.

Displaying record number 1170

Download this epitope record as JSON.

MAb ID	TB12
HXB2 Location	Tat(44-60) DNA(5960..6010)	Tat Epitope Map
Author Location	Tat(44-61 Lai/Bru)
Research Contact	Dr. J.-L. Guesdon, Institut Pasteur, Paris
Epitope	`GISYGRKKRRQRRPPQG`	Epitope Alignment
Subtype	B
Ab Type	Tat basic region
Neutralizing
Species (Isotype)	mouse(IgG)
Patient
Immunogen	vaccine
Keywords	subtype comparisons

Vaccine Details

Vaccine type	protein
Vaccine strain	B clade BRU
Vaccine component	Tat
Adjuvant	Complete Freund's Adjuvant (CFA)

Notes

Showing 1 of 1 note.

This is one of 5 anti-Tat murine monoclonal antibodies generated in this study. TB12 is clade B and D specific, and does not recognize Tat from clade A, C, or CRF01 (AE). It reacts strongly with aa 1-61, and is also able to react with aa 44-61, in the basic region involved in Tat uptake. Belliard2003 (subtype comparisons)

References

Showing 1 of 1 reference.

Displaying record number 1174

Download this epitope record as JSON.

MAb ID	TC15
HXB2 Location	Tat	Tat Epitope Map
Author Location	Tat( Lai/Bru)
Research Contact	Dr. J.-L. Guesdon, Institut Pasteur, Paris
Epitope
Subtype	B
Ab Type	N-term
Neutralizing
Species (Isotype)	mouse(IgG)
Patient
Immunogen	vaccine
Keywords	subtype comparisons

Vaccine Details

Vaccine type	protein
Vaccine strain	B clade BRU
Vaccine component	Tat
Adjuvant	Complete Freund's Adjuvant (CFA)

Notes

Showing 1 of 1 note.

TC15: This is one of 5 anti-Tat murine monoclonal antibodies generated in this study. It is conformational reacting only with intact protein. It reacts with B and D clade Tat proteins, and does not recognize Tat from clade A, C, or CRF01 (AE). Belliard2003 (subtype comparisons)

References

Showing 1 of 1 reference.

Displaying record number 1166

Download this epitope record as JSON.

MAb ID	polyclonal
HXB2 Location	Tat	Tat Epitope Map
Author Location	Tat
Epitope
Subtype	A, B, C, CRF01_AE, D
Ab Type
Neutralizing
Species (Isotype)	human(IgG)
Patient
Immunogen	HIV-1 infection
Country	France
Keywords	rate of progression, subtype comparisons

Notes

Showing 1 of 1 note.

Sera from 20 HIV-1 positive individuals were tested for their ability to react with Tat proteins from different clades, and were found to react with subtype A, B, and D, but not with subtype C or CRF01 (AE). Sera from 101 slow progressors and 42 fast progressors were tested for responses to Tat peptides, and compared to responses to gp41 peptide, as anti-Tat antibodies have been shown by others to be elevated in slow progressors. In this study, overall levels of Tat antibodies were not different in the two groups, however relative levels of antibodies to different Tat and gp41 peptides were observed. Belliard2003 (subtype comparisons, rate of progression)

References

Showing 1 of 1 reference.

Displaying record number 1172

Download this epitope record as JSON.

MAb ID	polyclonal
HXB2 Location	Tat	Tat Epitope Map
Author Location	Tat( Lai/Bru)
Epitope
Subtype	B
Ab Type	N-term
Neutralizing
Species (Isotype)	macaque(IgG)
Patient
Immunogen	SHIV infection, vaccine
Keywords	rate of progression

Vaccine Details

Vaccine type	peptide
Vaccine strain	B clade BRU
Vaccine component	Tat
Adjuvant	aluminum phosphate, CpG immunostimulatory sequence (ISS), Montanide (ISA 720)

Notes

Showing 1 of 1 note.

Macaques were immunized with different combinations of Tat peptides. Serum from these animals was able to inhibit Tat-induced apoptosis, and Tat antibodies are associated with long term survival. Anti-Tat antibodies generated in infected macaques tended to be restricted to the peptide 44-61, while sera from infected humans could react with several different peptides. Belliard2003 (rate of progression)

References

Showing 1 of 1 reference.

Displaying record number 1173

Download this epitope record as JSON.

MAb ID	polyclonal
HXB2 Location	Tat	Tat Epitope Map
Author Location	Tat( Lai/Bru)
Epitope
Subtype	B
Ab Type	N-term
Neutralizing
Species (Isotype)	rabbit(IgG)
Patient
Immunogen	SHIV infection, vaccine
Keywords	rate of progression

Vaccine Details

Vaccine type	peptide
Vaccine strain	B clade BRU
Vaccine component	Tat
Adjuvant	BSA, Complete Freund's Adjuvant (CFA)

Notes

Showing 1 of 1 note.

12 rabbits were immunized with different combinations of Tat peptides. Abs raised against peptide aa 8-53 did not react with the peptide 19-53, suggesting that the N-terminal region is important. Serum from these animals was able to inhibit Tat-induced apoptosis, and Tat antibodies in humans are associated with long term survival. Belliard2003 (rate of progression)

References

Showing 1 of 1 reference.

Displaying record number 1167

Download this epitope record as JSON.

MAb ID	polyclonal
HXB2 Location	gp160(595-607) DNA(8007..8045)	gp160 Epitope Map
Author Location	gp41(600-612)
Epitope	`IWGCSGKLICTTA`	Epitope Alignment
Subtype	B
Ab Type
Neutralizing
Species (Isotype)	human(IgG)
Patient
Immunogen	HIV-1 infection
Country	France
Keywords	rate of progression

Notes

Showing 1 of 1 note.

Sera from 101 slow progressors and 42 fast progressors were tested for responses to Tat peptides, and compared to responses to gp41 peptide 600-612, as anti-Tat antibodies had been shown by others to be elevated in slow progressors. Most patient sera react with this peptide, it is used in diagnostics. In this study, overall levels of Tat antibodies were not different in the two groups, however relative levels of antibodies to different Tat peptides and to this gp41 peptide were observed. Belliard2003 (rate of progression)

References

Showing 1 of 1 reference.